Personalis (NASDAQ:PSNL) Price Target Raised to $9.00

Personalis (NASDAQ:PSNL) had its price target increased by Lake Street Capital from $7.00 to $9.00 in a research report released on Wednesday morning,Benzinga reports. They currently have a buy rating on the stock.

Several other equities analysts have also weighed in on the stock. HC Wainwright restated a “buy” rating and set a $11.00 target price on shares of Personalis in a report on Wednesday. Needham & Company LLC restated a “buy” rating and set a $7.25 price objective on shares of Personalis in a research note on Wednesday.

Personalis Trading Down 0.2 %

Shares of Personalis stock opened at $5.59 on Wednesday. The business’s fifty day moving average price is $4.70 and its 200 day moving average price is $4.33. Personalis has a twelve month low of $1.12 and a twelve month high of $7.20. The stock has a market capitalization of $394.92 million, a P/E ratio of -3.33 and a beta of 1.75.

Personalis (NASDAQ:PSNL) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.31). Personalis had a negative net margin of 104.52% and a negative return on equity of 66.07%. The firm had revenue of $25.71 million during the quarter, compared to analyst estimates of $20.67 million. During the same period in the prior year, the firm earned ($0.51) earnings per share. As a group, sell-side analysts predict that Personalis will post -1.41 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in PSNL. IQ EQ FUND MANAGEMENT IRELAND Ltd boosted its holdings in Personalis by 42.5% in the third quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 15,103 shares of the company’s stock valued at $81,000 after purchasing an additional 4,504 shares during the last quarter. nVerses Capital LLC acquired a new position in shares of Personalis in the 3rd quarter valued at approximately $40,000. International Assets Investment Management LLC boosted its stake in shares of Personalis by 438.0% during the 3rd quarter. International Assets Investment Management LLC now owns 20,982 shares of the company’s stock valued at $113,000 after buying an additional 17,082 shares during the last quarter. Barclays PLC grew its position in shares of Personalis by 45.4% during the third quarter. Barclays PLC now owns 65,468 shares of the company’s stock worth $352,000 after buying an additional 20,444 shares in the last quarter. Finally, Quantbot Technologies LP bought a new stake in shares of Personalis in the third quarter worth $210,000. 61.91% of the stock is owned by institutional investors and hedge funds.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.